How is Merck & (MRK) doing?

Merck & is a company in the drug manufacturers, general industry, based in Rahway, NJ, worth $359.6B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Weak

Merck & shares are up 69% over the past year, 46 points ahead of the S&P 500. Its type is Faith Trade. Among large US stocks and funds it ranks in the 92nd percentile on market beat, the 55th on staying power and the 4th on business growth. It appears on 6 of our dashboards, including 1st on “Which companies do analysts expect to grow fastest?” and 5th on “Which companies invest the most in research?”.

$145.60+69% in a yearWorth $359.6B

Compare with LLY · BMY · ABBV · PFE · JNJ · AZN · AMGN · GILD · REGN

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

MRK against the S&P 500, past year

$100 a year ago. Merck & +69%, the S&P 500 +16%.

MRKS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Faith Trade

BeatingSteadySlowingBought

Beating the market steadily with buyers in control, though its business growth trails most. The price is ahead of the numbers.

NovDecJanFebMarAprMayJunJulAugSepNow

Faith Trade since Sep; Speculative Pop before that.

Also Faith Trade (62 in all): IQV · CRL · RVTY · ACHC · PFE · MRNA

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

MRK, past year+69%9 of 86 in the group

Rest of the group+20%equal-weighted

S&P 500+16%past year

Merck & is +69% over the past year, against +20% for the rest of the group and +16% for the S&P 500. It ranks 9th of 86 in Health care.

MRKRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsLLY Lilly (Eli)+39%BMY Bristol Myers Squibb+33%ABBV AbbVie+20%PFE Pfizer+10%JNJ Johnson & Johnson+38%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Merck & typically moves 2.5% in a day, about usual for it, and it swings less than 73% of large US stocks.

Typical day2.5%about $3.58 a share

Its usual2.5%about usual, 1.0× its year’s average

Against the S&P 5002.3×the index’s typical day is 1.1%

Unusual day±4.9%twice its typical day

Deepest fall, past year−12%now 7% below its high

In the S&P’s down weeks33%of the index’s fall, three years; beta 0.3

Typical daily move (ATR)Its year’s average 2.51%

MRK on our dashboards

Every question where Merck & appears, in the order of the home page, with its reading and place in that table. Select a question to open it with MRK highlighted. Select a column to sort.

Question	Reading	Place	Details
Which companies are worth the most? What’s leading	–	36 of 50	Market value $359.6B · Places, 1Y +2 · Value, 1Y +63%
Which companies are most exposed to China? The economy and rates	15Light	30 of 35	Share of sales 3.0% · China sales $1.9B · 3-year change −5.8 pts
Which companies do analysts expect to grow fastest? Earnings	100Fast	1 of 60	EPS growth +248% · This year 2.74 · Next year 9.53
Who is beating its rivals? Leading stocks	89Ahead	58 of 60	3M +11 pts · 1Y +46 pts · Rivals LLY, BMY, ABBV, PFE
Which companies invest the most in research? Business quality	98Heavy	5 of 60	R&D / revenue 42.7% · R&D a year $28.4B · R&D, 1Y +66%
What is Congress trading? Who’s buying and selling	3Bought	23 of 60	Buying 2 · Selling 1 · Bought $65K

Go deeper on Stox

MRK’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open MRK on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see MRK’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›LLY · Lilly (Eli) ›BMY · Bristol Myers Squibb ›ABBV · AbbVie ›PFE · Pfizer ›